Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tumor specific killer cell preparation and preparation method thereof

A tumor-specific, cell-killing technology, which is applied in the field of tumor-specific cell-killing preparations and its preparation, can solve the problems of low clinical effective rate and low tumor killing rate, and achieve improved killing efficiency, excellent curative effect, and high recovery rate. Effect

Active Publication Date: 2014-05-21
浓孚雨医药河北有限公司
View PDF2 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The main purpose of the present invention is to solve the problems of low tumor killing rate and low clinical effective rate of the current DC-CIK-CTL method, and the application of this technology can significantly improve the killing efficiency of tumors, improve clinical effective rate and objective curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor specific killer cell preparation and preparation method thereof
  • Tumor specific killer cell preparation and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] 1. Precautions before blood collection:

[0048] Because radiotherapy and chemotherapy will greatly affect the content and function of initial T cells in peripheral blood and bone marrow, it is more appropriate to collect peripheral blood mononuclear cells after radical surgery or one month after radiotherapy and chemotherapy in patients with advanced tumors. When the number of peripheral blood leukocytes is low, recombinant human granulocyte-macrophage-colony-stimulating factor for injection (rhGM-CSF) can be injected subcutaneously for bone marrow mobilization. For tumor patients with multiple bone marrow metastases or low bone marrow hematopoietic function, the content and function of initial T cells in peripheral blood are poor, so it is not suitable to collect peripheral blood mononuclear cells.

[0049] 2. Collection of peripheral blood mononuclear cells:

[0050] Use the COBESPECTRA cell component separator, set the parameters and program according to the instru...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a tumor specific killer cell preparation and a preparation method thereof. A specific killer cell is a mixture of DC (Dendritic Cell) vaccine, and CIK (Cytokine Induced Killer) and CTL (Cytotoxic Lymphocyte) cells. The preparation contains thymopentin; the preparation is mixed with the killer cells so as to have the effect of obviously improving the treatment effect.

Description

technical field [0001] The invention relates to a new technology of anti-tumor cell immunotherapy, in particular to a novel tumor-specific killer cell (DC-CIK-CTL) preparation derived from initial T cells and a preparation method thereof. Background technique [0002] Chinese patent 2012101271586 describes a method for preparing effector cells, that is, using a mixture of CD4+ and CD8+ initial T cells to prepare DC-CIK-CTL effector cells, and at the same time providing a compound preparation to interfere with the tumor microenvironment, thereby breaking tumor immunity Tolerance, based on this new technology of effector cell reinfusion therapy. The preparation method of the DC-CIK-CTL effector cells is as follows: obtaining monocytes from peripheral blood, and separating DC cells and total T cells in vitro. After 5 days of culture and expansion, DC cells are added with the patient's own tumor-associated whole antigen to mature on the 7th day, and the tumor-specific DC vaccin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P35/00C12N5/0783C12N5/0784A61K38/08
Inventor 蔡建辉徐建强杨小岗胡玲玲
Owner 浓孚雨医药河北有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com